

What Is Claimed Is:

1. An isolated polypeptide selected from the group consisting of:
 - (a) a polypeptide having an amino acid sequence identical to a portion of the amino acid sequence of SEQ ID NO:2, wherein the amino terminus of said polypeptide is residue 4 of SEQ ID NO:2 and the carboxy terminus is residue m, wherein m is any residue from residue 48 to residue 93 of SEQ ID NO:2; and
 - (b) a polypeptide having an amino acid sequence identical to that of (a), except for at least one amino acid substitution.
2. The polypeptide of claim 1, which is (a).
3. The polypeptide of claim 1, which is (b).
4. The polypeptide of claim 2, which is an antagonist of Chemokine β -6 (Ck β -6).
5. The polypeptide of claim 3, which is an antagonist of Chemokine β -6 (Ck β -6).
6. The polypeptide of claim 2, having the amino acid sequence Pro (4) to Arg (73) of SEQ ID NO:2.
7. The polypeptide of claim 2, with a Met residue at the N-terminus.
8. The polypeptide of claim 3, with a Met residue at the N-terminus.
9. The polypeptide of claim 6, with a Met residue at the N-terminus.

10. An isolated nucleic acid molecule encoding the polypeptide of claim 1.

11. A method for making a recombinant vector comprising inserting the nucleic acid molecule of claim 10 into a vector.

12. A recombinant vector produced by the method of claim 11.

13. A method of making a recombinant host cell comprising introducing the recombinant vector of claim 12 into a host cell.

14. A recombinant host cell produced by the method of claim 13.

15. A method for producing a polypeptide comprising culturing the host cell of claim 14 under conditions such that said polypeptide is expressed and recovering said polypeptide.

16. A method for treating diseases and disorders selected from the group consisting of: autoimmune diseases, inflammation, rheumatoid arthritis, atherosclerosis, allergies, dermatitis, chronic urticaria, adult respiratory distress syndrome, asthma, rhinitis, eczema and infectious diseases comprising: administering to a patient in need thereof an effective amount of the polypeptide of claim 1.

17. The method of claim 16, wherein said polypeptide inhibits activation or mobilization of eosinophils.

18. The method of claim 16, wherein said polypeptide inhibits activation or mobilization of basophils.

19. The method of claim 16, wherein said polypeptide binds Chemokine Receptor-3.

20. An isolated polypeptide selected from the group consisting of:

(a) a polypeptide having an amino acid sequence identical to a portion of the amino acid sequence of SEQ ID NO:2, wherein the amino terminus of said polypeptide is residue 2 of SEQ ID NO:2 and the carboxy terminus is residue m, wherein m is any residue from residue 48 to residue 93 of SEQ ID NO:2; and

(b) a polypeptide having an amino acid sequence identical to a portion of the amino acid sequence of SEQ ID NO:2, wherein the amino terminus of said polypeptide is residue 3 of SEQ ID NO:2 and the carboxy terminus is residue m, wherein m is any residue from residue 48 to residue 93 of SEQ ID NO:2; and

(c) a polypeptide having an amino acid sequence identical to a portion of the amino acid sequence of SEQ ID NO:2, wherein the amino terminus of said polypeptide is residue 1 of SEQ ID NO:2 and the carboxy terminus is residue m, wherein m is any residue from residue 48 to residue 92 of SEQ ID NO:2;

(d) a polypeptide having an amino acid sequence identical to that of (a), except for at least one amino acid substitution;

(e) a polypeptide having an amino acid sequence identical to that of (b), except for at least one amino acid substitution; and

(f) a polypeptide having an amino acid sequence identical to that of (c), except for at least one amino acid substitution.

21. The isolated polypeptide of claim 20, which is (a).

22. The isolated polypeptide of claim 20, which is (b).
23. The isolated polypeptide of claim 20, which is (c).
24. The isolated polypeptide of claim 20, which is (d).
25. The isolated polypeptide of claim 20, which is (e).
26. The isolated polypeptide of claim 20, which is (f).
27. The isolated polypeptide of claim 20, which is an agonist of Ck β -
- 6.
28. The isolated polypeptide of claim 20, having an amino acid sequence of SEQ ID NO:2 selected from the group consisting of: Val (1) to Arg (73); Val (2) to Arg (73); Ile (3) to Arg (73); Val (1) to Arg (75); Val (1) to Ala (73); Val (2) to Ala (76); and Val (1) to Ala (78).
29. The polypeptide of claim 20, with a Met residue at the N-terminus.
30. The polypeptide of claim 28, with a Met residue at the N-terminus.
31. An isolated nucleic acid molecule encoding the polypeptide of claim 20.
32. A method for making a recombinant vector comprising inserting the nucleic acid molecule of claim 31 into a vector.
33. A recombinant vector produced by the method of claim 32.

34. A method of making a recombinant host cell comprising introducing the recombinant vector of claim 33 into a host cell.

35. A recombinant host cell produced by the method of claim 34.

36. A method for producing a polypeptide comprising culturing the host cell of claim 35 under conditions such that said polypeptide is expressed and recovering said polypeptide.

37. A method for activating or mobilizing basophils or eosinophils comprising: administering to a patient in need therof an effective amount of the polypeptide of claim 20.

38. The method of claim 37, wherein said polypeptide is injected into said patient to increase local eosinophil or basophil infiltration.

39. The method of claim 37, wherein said polypeptide stimulates histamine release.

40. A method of myeloprotection comprising an effective amount of the polypeptide of claim 20 to a patient undergoing chemotherapy.